Tatva Chintan’s Capacity Has Nearly Tripled, But Revenue Has Barely Moved; When Will the Assets Pay Off?
Tatva Chintan has spent the past few years expanding its manufacturing capacity ahead of demand, but revenue has not increased at the same pace. With utilization now recovering and new products gaining traction, the key question is when the enlarged asset base will start generating stronger and more consistent returns.
Tatva Chintan Pharma Chem was recently trading around ₹1,739 per share , with a market capitalization of roughly ₹4,068 crore and a P/E of around 78x . The stock's 52-week range was approximately ₹1,022–₹1,880 .
Capacity Has Outpaced Revenue
The scale of the expansion is striking. Combined reactor capacity increased by around 169% , from 294 KL to 791 KL, which is an increment of 497KL, between FY22 and FY26. The company's Dahej facility was the primary driver, with installed reactor capacity increasing from 204 KL to 698 KL , while Ankleshwar capacity remained broadly stable.
Revenue, however, increased by only about 17% over the same four-year period. It also did not move in a straight line, falling from ₹433.6 crore in FY22 to ₹382.7 crore in FY25 before recovering strongly in FY26.
This highlights why capacity additions alone cannot be treated as a growth indicator. New assets create potential production capacity, but their economic value depends on customer demand, product mix, and utilization.
Utilisation Is Starting to Recover
The utilisation trend provides an important part of the explanation. Total reactor utilization was 77.61% in FY23 , before falling to 64.11% in FY25 as the company added significant Dahej capacity. By FY26, utilisation had recovered to 76.90% , according to Tatva Chintan's FY26 annual-report data.
The recovery is significant because it suggests that the expanded capacity is gradually being absorbed. But the company still has additional headroom before the entire installed base reaches mature utilization levels. The question therefore shifts from "How much capacity has Tatva Chintan added?" to "How quickly can that capacity be filled with profitable volumes?"
FY26 Shows Operating Leverage
FY26 provides the first strong evidence that higher utilisation can translate into disproportionately better profitability. Revenue increased 32% YoY to ₹505.9 crore , while EBITDA jumped 172% to ₹93.2 crore . EBITDA margin increased from 8.9% in FY25 to 18.4% in FY26 . PAT also rose sharply to ₹42.1 crore from ₹5.7 crore .
This is important for the capacity-payback argument. Once a larger portion of the fixed manufacturing base starts getting utilised, additional volumes can potentially flow through the existing cost structure with relatively stronger incremental profitability. Q1 FY27 continued that trend. Revenue increased 43% YoY to ₹167.1 crore , while EBITDA rose 86% to ₹32.3 crore and PAT increased 140% to ₹16 crore .
Revenue Productivity Still Needs to Improve
A useful way to assess the return from the expansion is to compare revenue with installed reactor capacity. On a simple calculation using year-end capacity, FY22 generated roughly ₹1.47 crore of revenue per KL of installed capacity , while FY26 generated around ₹0.64 crore per KL .
This does not mean the assets are necessarily uneconomic because reactor capacity is only one component of manufacturing capability and different products have different economics. However, the calculation highlights the underlying issue: revenue has not yet increased in proportion to the manufacturing footprint . For the asset base to become more productive, utilization needs to remain elevated while higher-value products contribute a greater share of sales.
New Products Could Improve Asset Utilization
Tatva Chintan is trying to fill the expanded capacity through multiple growth avenues rather than relying on its legacy portfolio. Its FY26 revenue mix included Structure Directing Agents at 41%, PTC at 23%, PASC at 32% and Electrolyte Salts at 3% .
The company is seeing stronger demand across several of these categories. In Q1 FY27, Phase Transfer Catalysts revenue increased 47% YoY , SDA revenue increased 47% , and Pharma & Agro Intermediates and Specialty Chemicals revenue increased 25% .
Management also said recently commercialized pharma and agrochemical molecules are generating repeat orders, while a pharma intermediate began commercial production in Q1 FY27.
These newer products could matter because they give Tatva Chintan additional avenues to utilise its expanded infrastructure rather than depending entirely on existing products.
Semiconductor Is A Long-Term Option
The company's semiconductor opportunity is another potential demand driver, although it should not be treated as an immediate revenue contributor. Tatva Chintan delivered its first plant-scale semiconductor-related batch during Q1 FY27, and the product was successfully qualified by the customer. Management said further scale-up and qualification stages are required, with commercialization expected to take time.
Management specifically said it does not expect major-volume semiconductor commercialisation before Q4 FY28 , indicating that this opportunity should be viewed as a longer-term potential growth driver rather than a near-term utilisation solution.
Another 344 KL Is Coming
The interesting part is that Tatva Chintan is preparing to add capacity again. The company has approved a 344 KL greenfield manufacturing facility at Dahej-III , with an investment of approximately ₹200 crore and an expected completion period of around 21 months . The project is intended to support new products, domestic demand and future growth.
Management believes the existing facilities will begin approaching their practical limits as revenue moves beyond roughly ₹800–850 crore , making the new site necessary for the next phase of expansion. This makes execution of the current capacity particularly important. Another large capacity addition could recreate the same problem if demand does not scale alongside it.
The Next Test Is Demand Absorption
The company is targeting 25–30% revenue growth for FY27 and expects EBITDA margins of around 20–22% . The first quarter has started strongly, but sustaining that trajectory across the full year will be more important than one strong quarter.
The encouraging factor is that management says customer demand and visibility are currently strong across its major segments. At the same time, raw-material shortages affected the electrolyte business during Q1, highlighting that execution can still be influenced by supply-side disruptions.
Conclusion
Tatva Chintan's capacity story has moved into a different phase. The company has already expanded reactor capacity from 294 KL to 791 KL , but FY26 was the first year in which the larger asset base began translating more visibly into revenue growth and operating leverage.
The recovery in utilisation, stronger demand across PTC, SDA and PASC, and the commercialisation of newer products provide potential avenues for further absorption of capacity. Q1 FY27's 43% revenue growth and 86% EBITDA growth add to that evidence.
However, another 344 KL of capacity is now being added at Dahej-III. The key issue will therefore be whether Tatva Chintan can increase revenue and EBITDA per unit of installed capacity faster than it expands its manufacturing base.
For investors, the most important monitorables are reactor utilisation, revenue productivity per KL, EBITDA margins, new-product commercialization, and the pace at which the new Dahej facility is absorbed . The success of this investment cycle will ultimately depend not on how much capacity Tatva Chintan builds, but on how efficiently it converts that capacity into sustainable revenue and cash-generating assets .